New pill could melt fat in people with obesity
NCT ID NCT07169942
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new oral drug called aleniglipron (GSBR-1290) in 71 adults with obesity (BMI ≥30). Participants take the drug or a placebo daily for 40 weeks. Researchers measure changes in body fat, waist size, and weight using special scans. The goal is to see if the drug safely reduces fat and improves body composition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aleniglipron (GSBR-1290)
What this could lead to
If successful, this could lead to a new oral medication for obesity that reduces body fat and improves body composition.
What could go wrong
This is an early Phase 2 trial with only 71 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Phoenix, Arizona, 85020, United States
-
Research Site
Chicago, Illinois, 60602, United States
-
Research Site
Richfield, Minnesota, 55423, United States
-
Research Site
City of Saint Peters, Missouri, 63303, United States
-
Research Site
Rochester, New York, 14609, United States
-
Research Site
Wilmington, North Carolina, 28401, United States
-
Research Site
Norman, Oklahoma, 73069, United States
-
Research Site
Moncks Corner, South Carolina, 29461, United States
-
Research Site
North Charleston, South Carolina, 29405, United States
-
Research Site
Austin, Texas, 78704, United States
-
Research Site
San Antonio, Texas, 78240, United States